Linc

Linc FCF Conversion

FCF Conversion Rate (FCF/EBITDA) of Linc (LINC.ST) as of Nov 20, 2026.

FCF Conversion

0.00

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Linc is 2025 0.00 . FCF Conversion Rate (FCF/EBITDA) of Linc was 2024 2.28 % . It decreases by % lower compared to the previous year.

The Linc FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-6.22 SEK
Jan 1, 2019
0.20 SEK
Jan 1, 2020
-1.76 SEK
Jan 1, 2021
1,178.32 SEK
Jan 1, 2022
31.54 SEK
Jan 1, 2023
-13.01 SEK
Jan 1, 2024
2.28 SEK
Jan 1, 2025
0.00 SEK
The Linc FCF Conversion history
YEARFCF ConversionYoY
0.00-100.00%
2.28 %-117.53%
-13.01 %-141.24%
31.54 %-97.32%
1,178.32 %-67,224.04%
-1.76 %-991.45%
0.20 %-103.17%
-6.22 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Linc Stock analysis

What does Linc do? Linc AB generates revenue through long-term share ownership in Nordic life science companies, focusing on pharmaceutical and medical technology sectors. The company invests in both private and public firms, including early-stage drug development and operational medical technology companies. Linc Invest actively supports portfolio companies by collaborating with management, founders, and boards to unlock growth potential and drive expansion. Its industrial network enables strategic participation in nomination committees and development planning. The firm targets Nordic life science product-oriented companies, prioritizing pharmaceuticals and medical technology. Investments span research and operational phases, with drug development typically occurring earlier than in medical technology. Linc AB maintains a hands-on approach as a long-term owner, leveraging its network to assist portfolio companies in achieving ambitious development goals. Linc AB's business model centers on active ownership and strategic partnerships within the Nordic life science ecosystem. It focuses on companies with strong product pipelines, particularly in pharmaceuticals, where investments often occur during initial development stages. The company's role as a supportive shareholder drives value creation through collaborative governance and targeted expansion strategies. Linc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Linc stock

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Linc since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Linc with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Linc

All Key Metrics — Linc